] . Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50. 
(887.01 KB)
(887.01 KB). Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665. (237.99 KB)
(237.99 KB). CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22. (1011.52 KB)
(1011.52 KB). Influence of Gestational Age at Initiation of Antihypertensive Therapy: Secondary Analysis of CHIPS Trial Data (Control of Hypertension in Pregnancy Study). Hypertension. 2018;71(6):1170-1177. (303.94 KB)
(303.94 KB). Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension. 2017;69(3):469-474. (378.99 KB)
(378.99 KB). External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711. (149.83 KB)
(149.83 KB). Global Pregnancy Collaboration symposium: Prepregnancy and very early pregnancy antecedents of adverse pregnancy outcomes: Overview and recommendations. Placenta. 2017;60:103-109. (216.45 KB)
(216.45 KB). Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237. (986.49 KB)
(986.49 KB). Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76. (803.67 KB)
(803.67 KB). The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159. (476.19 KB)
(476.19 KB). Collaboration to Understand Complex Diseases: Preeclampsia and Adverse Pregnancy Outcomes. Hypertension. 2016;67(4):681-7. (400.35 KB)
(400.35 KB). Community health worker knowledge and management of pre-eclampsia in rural Karnataka State, India. Reprod Health. 2016;13(Suppl 2):113. (629.01 KB)
(629.01 KB). Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51. (153.93 KB)
(153.93 KB). Control of hypertension in pregnancy--if some is good, is more worse?. N Engl J Med. 2015;372(5):475-6. (342.05 KB)
(342.05 KB). Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21. (505.41 KB)
(505.41 KB). Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76. (1.88 MB)
(1.88 MB). Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61. (463.16 KB)
(463.16 KB). Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8. (515.75 KB)
(515.75 KB). Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62. (317.15 KB)
(317.15 KB). Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877. (1021.64 KB)
(1021.64 KB). Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8. (85.31 KB)
(85.31 KB). Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152. (834.74 KB)
(834.74 KB)Management of the second stage of labor. Int J Gynaecol Obstet. 2012;119(2):111-6. (468.69 KB)
(468.69 KB). The Maternal and Newborn Health Registry Study of the Global Network for Women's and Children's Health Research. Int J Gynaecol Obstet. 2012;118(3):190-3. (98.99 KB)
(98.99 KB). The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81. (233.18 KB)
(233.18 KB). Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. (280.12 KB)
(280.12 KB). The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120. (322.85 KB)
(322.85 KB). Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714. (383.37 KB)
(383.37 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB). Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27. (201.46 KB)
(201.46 KB). The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8. (370.8 KB)
(370.8 KB). Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809. (269.78 KB)
(269.78 KB)